Courts and regulatory bodies have taken significant actions affecting biotech and healthcare sectors. A federal judge temporarily halted sweeping staff layoffs at the U.S. Department of Health and Human Services, deeming them likely unlawful and enjoining further implementation amid multiple lawsuits. The FDA approved companion diagnostics supporting new oncology drugs, while CMS and OIG are increasing oversight on Medicare payments and reimbursement practices. Vaccine policy remains under legislative scrutiny following allegations against Pfizer. These developments illustrate heightened legal and regulatory scrutiny shaping the industry’s operational environment.